Gut Leakage' in Dengue

Dengue fever is a mosquito-borne viral disease affecting hundreds of millions of people each year, with the highest burden in tropical countries like Bangladesh. When dengue becomes severe, patients often develop alarming gastrointestinal symptoms — abdominal pain, vomiting, and diarrhoea — that signal a dangerous escalation. This study investigates whether 'gut leakage' (intestinal barrier dysfunction) is a key driver of that escalation: the idea being that the dengue virus damages the gut wall, allowing microbial metabolites and bacterial products to spill into the bloodstream. Once in the blood, these gut-derived molecules could trigger inflammatory cascades that worsen the disease, potentially contributing to the plasma leakage and vascular instability that makes severe dengue life-threatening. The research team, based at the University of Oxford and working in Bangladesh, plans to detect markers of gut translocation in dengue patients to test this hypothesis. If confirmed, gut barrier dysfunction could become a new therapeutic target — and perhaps a biomarker for predicting who will deteriorate. The WHO has flagged dengue as a priority pathogen with pandemic potential, making mechanistic studies like this one globally important.

• This study is not yet recruiting (expected start May 2026) and has not yet reported results; no quantitative findings are currently available.
• The central hypothesis under investigation is that gut leakage — translocation of gut metabolites into the bloodstream — initiates and amplifies the inflammatory processes underlying severe dengue, including plasma leakage.
• Gastrointestinal warning signs (abdominal pain, vomiting, diarrhoea) are recognised WHO criteria for severe dengue and provide the clinical rationale for focusing on the gut-barrier axis as a mechanistic pathway.

This is a prospective observational clinical study registered on ClinicalTrials.gov (NCT07602920), led by the University of Oxford and set to be conducted in Bangladesh. The study will enrol dengue-infected participants and measure biomarkers of intestinal barrier dysfunction — specifically markers of gut metabolite translocation into the bloodstream — to evaluate whether gut leakage is present and correlates with disease severity. The protocol is not yet fully published, so precise sample size, follow-up duration, and the full biomarker panel are not available at this time. Status is 'not yet recruiting' as of the registration date; enrolment is anticipated from May 2026 onward.

Because the study has not yet recruited participants or reported data, all findings described are hypothetical and reflect the investigators' a priori reasoning rather than empirical results — confidence in any mechanistic claims is low at this stage. The observational design (as implied by the hypothesis-testing framing) will be able to establish association between gut leakage markers and dengue severity, but cannot alone prove causality or determine whether barrier disruption precedes or follows systemic inflammation. Conducting the study in a single high-endemic country (Bangladesh) may limit generalisability to dengue populations in Southeast Asia, Latin America, or the Pacific, where circulating serotypes and host genetics differ. The next critical experiment would be an interventional trial testing gut-barrier-protective agents (e.g., probiotics or tight-junction stabilisers) in dengue patients stratified by leakage biomarker levels to establish therapeutic relevance.

This study extends the corpus's central theme of intestinal barrier dysfunction by applying it to an acute viral infection context rather than the chronic inflammatory or dietary settings explored elsewhere. It directly parallels [§155], which evaluates Saccharomyces boulardii's effects on intestinal barrier function, as both studies use gut permeability and translocation as their primary mechanistic endpoints — a reader comparing them would see the same biological target approached from opposite angles: pathological disruption versus therapeutic restoration. The gut-leakage hypothesis also parallels [§149], which demonstrates that environmental stressors (heat and exercise) can disrupt gut microbiota and promote microbial translocation, suggesting that diverse systemic insults — viral, thermal, or physical — converge on the same barrier-failure pathway. More broadly, the study contextualises findings from [§148], which documents gut leakiness in a metabolic disease model and proposes dietary intervention, reinforcing the emerging view that translocation of gut contents is a transdiagnostic mechanism operating across infectious, inflammatory, and metabolic disease states. Together, these articles suggest the corpus is building toward a unified mechanistic framework in which gut barrier integrity is a shared vulnerability across conditions as different as dengue infection and high-fat-diet-induced dyslipidaemia.

• Saccharomyces Boulardii CNCM I-745 on Intestinal Barrier Function
  Directly investigates the same endpoint — intestinal barrier function and permeability markers — but from a therapeutic (probiotic intervention) rather than pathological perspective, making it the closest mechanistic counterpart.
• Combined heat and exercise stress disrupt gut microbiota and promote microbial translocation
  Demonstrates that a non-infectious systemic stressor (combined heat and exercise) drives microbial translocation via gut barrier disruption, providing a comparative model for how diverse triggers produce the same gut-leakage phenotype central to this dengue study.
• Dietary Intervention with Brown Top Millet Starch Ameliorates Dyslipidaemia and Gut Leakiness in High Fat Diet Fed Models
  Quantifies gut leakiness as an outcome measure in a metabolic disease model and tests a dietary corrective, offering a methodological template for how translocation biomarkers can be operationalised — directly relevant to this study's planned biomarker detection approach.
• The Role of Vitamin D in Inflammatory Bowel Disease: Clinical Relevance and Therapeutic Potential
  Examines vitamin D's role in gastrointestinal barrier integrity within inflammatory bowel disease, relevant because vitamin D-mediated tight-junction regulation may represent a host-defence mechanism that dengue virus disrupts, linking immune-nutritional status to gut-leakage susceptibility.